Research Output per year
Personal profile
Education
- 中山醫學院醫學系學士
Experience
- 1992年08月 ~迄今 胃腸肝膽科醫師
Fingerprint Dive into the research topics where Pin-Nan Cheng is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 28 Similar Profiles
Chronic Hepatitis C
Medicine & Life Sciences
Hepacivirus
Medicine & Life Sciences
Chronic Hepatitis B
Medicine & Life Sciences
Virus Diseases
Medicine & Life Sciences
Ribavirin
Medicine & Life Sciences
Genotype
Medicine & Life Sciences
Hepatitis B virus
Medicine & Life Sciences
Taiwan
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1996 2019
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
Huang, C. F., Hung, C. H., Cheng, P. N., Bair, M. J., Huang, Y. H., Kao, J. H., Hsu, S. J., Lee, P. L., Chen, J. J., Chien, R. N., Peng, C. Y., Lin, C. Y., Hsieh, T. Y., Cheng, C. H., Dai, C. Y., Huang, J. F., Chuang, W. L. & Yu, M. L., 2019 Jul 19, In : The Journal of infectious diseases. 220, 4, p. 557-566 10 p.Research output: Contribution to journal › Article
Chronic Hepatitis C
Viral Load
Fibrosis
Randomized Controlled Trials
Genotype
1
Citation
(Scopus)
Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients
Cheng, P-N., Chen, Z-Y., Chiu, Y-C., Chiu, H-C. & Tsai, L-M., 2019 Dec 1, In : Scientific reports. 9, 1, 1426.Research output: Contribution to journal › Article
Vascular Stiffness
Antiviral Agents
Fibrosis
Chronic Hepatitis C
Blood Pressure
Combined transarterial embolization/ chemoembolization-based locoregional treatment with sorafenib prolongs the survival in patients with advanced hepatocellular carcinoma and preserved liver function: A propensity score matching study
Chien, S. C., Chen, C-Y., Cheng, P-N., Liu, Y. S., Cheng, H-C., Chuang, C-H., Chang, T-T., Chiu, H. C., Lin, Y-J. & Chiu, Y-C., 2019 Jan 1, In : Liver Cancer. 8, 3, p. 186-202 17 p.Research output: Contribution to journal › Article
Propensity Score
Hepatocellular Carcinoma
Survival
Liver
Liver Neoplasms
2
Citations
(Scopus)
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
Yu, M. L., Hung, C. H., Huang, Y. H., Peng, C. Y., Lin, C. Y., Cheng, P-N., Chien, R. N., Hsu, S. J., Liu, C. H., Huang, C. F., Su, C. W., Huang, J. F., Liu, C. J., Kao, J. H., Chuang, W. L., Chen, P. J. & Chen, D. S., 2019 Feb 1, In : Journal of the Formosan Medical Association. 118, 2, p. 556-564 9 p.Research output: Contribution to journal › Article
Open Access
Ribavirin
Genotype
Safety
Infection
Galectin 3
2
Citations
(Scopus)
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: Final results from the randomized C-CORAL study
on behalf of the C-CORAL Investigators, 2019 Jan, In : Journal of Gastroenterology and Hepatology (Australia). 34, 1, p. 12-21 10 p.Research output: Contribution to journal › Article
Open Access
Russia
Hepacivirus
Genotype
Safety
Infection